Bemnifosbuvir

Summary

Bemnifosbuvir (CHEMBL5095404) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including severe acute respiratory syndrome and liver disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 6
• Chemistry: 581.5 Da · C24H33FN7O7P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095404
Name	Bemnifosbuvir
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	122527455
Molecular formula	C24H33FN7O7P
Molecular weight	581.5
InChIKey	OISLSHLAXHALQZ-HEOQURLSSA-N

SMILES: C[C@@H](C(=O)OC(C)C)NP(=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=NC3=C(N=C(N=C32)N)NC)(C)F)O)OC4=CC=CC=C4

IUPAC name: propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate

Also known as: Arbemnifosbuvir, AT-511, AT-527 free base, Bemnifosbuvir, BEMNIFOSBUVIR

Parent form; salt/anhydrous children: CHEMBL5095037

Patent coverage: 61 distinct patent families (177 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 168 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
liver disorder	1	MONDO:0005154	EFO:0001421

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE1	4
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05629962	PHASE3	COMPLETED	SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
NCT05904470	PHASE2	COMPLETED	A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
NCT05724693	PHASE1	COMPLETED	Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function
NCT05905484	PHASE1	COMPLETED	Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects
NCT05905497	PHASE1	COMPLETED	The Study of Bemnifosbuvir in Healthy Japanese Subjects
NCT07272889	PHASE1	COMPLETED	Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).